BioAegis Therapeutics Receives FDA Fast Track Designation for Lead Product, Recombinant Human Gelsolin, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
NORTH BRUNSWICK, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate, recombinant human plasma gelsolin (rhu-pGSN) for the treatment of acute respiratory distress syndrome (ARDS). The company's portfolio is built around gelsolin, a highly conserved and critical immune regulatory protein which rebalances dysfunctional inflammation without suppressing immune function.
What Fast Track Designation Means to BioAegis and PatientsThe FDA Fast Track program is designed to facilitate the development of new therapies for serious conditions with high unmet medical needs. Fast Track status enables more frequent interactions with the FDA, including rolling review of the marketing application, and eligibility for priority review, which can significantly accelerate time to market. For BioAegis, this designation highlights the therapeutic promise of rhu-pGSN and provides a clear regulatory pathway to expedite its development as a treatment for ARDS.
ARDS is a life-threatening condition marked by severe pulmonary inflammation and fluid accumulation in the lungs. Even with aggressive medical management, 40% of ARDS patients do not survive, and those who do may suffer from long-term complications, including impaired lung function and reduced quality of life.
In the U.S. alone, ARDS affects over 500,000 patients per year, or roughly 10% of all ICU admissions. With no effective pharmacological therapies currently available for ARDS and its high mortality rate driven by excessive inflammation, there is an urgent need for innovative treatments in this field. BioAegis is currently enrolling patients in a 600-patient global Phase 2b trial to evaluate the efficacy and safety of rhu-pGSN in moderate to severe ARDS (NCT05947955).
As part of the Fast Track designation, rhu-pGSN may also be made available to patients through the FDA's Expanded Access or Compassionate Use program, offering a potential treatment option for those who are not eligible for clinical trials and have no alternative therapies.
'Receiving FDA Fast Track designation is a critical milestone for BioAegis and further validates the potential of gelsolin to address the urgent and unmet needs of ARDS patients. Despite the high mortality of ARDS and its major strain on our healthcare system, no approved treatments currently exist. Fast Track status brings us closer to delivering an effective therapy for this devastating condition,' states Susan Levinson, PhD., CEO of BioAegis Therapeutics.
Gelsolin: A Multitasking Protein for Complex Inflammatory Conditions Gelsolin holds immense promise as a therapeutic intervention for serious acute and chronic conditions due to its multifaceted mechanism of action. In critical illness, gelsolin levels collapse, causing adverse outcomes. Supplementing gelsolin addresses this deficit directly—restoring immune balance while preserving host defense—and has been shown in both animals and humans to:
Modulate the activation of the NLRP3 inflammasome.
Enhance uptake and killing of microbial pathogens by innate immune cells.
Bind to and remove harmful inflammatory mediators and toxic actin released from damaged cells.
Regulate macrophage phenotype to modulate inflammation.
Supplementation with the recombinant gelsolin protein holds promise to address the overzealous inflammatory response associated many inflammatory diseases without suppressing immune function.
About BioAegisBioAegis Therapeutics Inc. is a NJ-based clinical-stage, private company whose mission is to capitalize on a key regulatory component of the body's immune system, plasma gelsolin, to prevent adverse outcomes in diseases driven by inflammation.
BioAegis has the exclusive license to broad, worldwide intellectual property through Harvard-Brigham and Women's Hospital. It holds over 40 patents issued for coverage of inflammatory disease, infection, renal failure, neurologic disease, and frailty. BioAegis will also have U.S. biologics exclusivity and has recently filed new IP in areas of unmet need.
BioAegis' lead product, rhu-pGSN, is currently being studied in a 600-patient global Phase 2 trial for patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS). This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50123C00067.
Investor Inquiries:Steven Cordovano203-952-6373scordovano@bioaegistx.com
Media Inquiries:Christine Laganaclagana@bioaegistx.com
This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management's plans, objectives, and strategies. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.Melden Sie sich an, um Ihr Portfolio aufzurufen.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 hours ago
- Associated Press
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Applies for FDA Commissioner's National Priority Voucher for IV Ketamine NRX-100
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 30, 2025 ( NEWMEDIAWIRE ) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, is accelerating its push toward regulatory approval of NRX-100, a preservative-free intravenous ketamine formulation. The company has filed an application under the newly created FDA Commissioner's National Priority Voucher ('CNPV') program, which promises significantly shortened review timelines for drugs that meet urgent U.S. health priorities ( ). The new CNPV program, announced by FDA Commissioner Marty Makary on June 17, is intended to bring promising treatments to market more quickly. Makary had previously identified psychedelic drugs for treatment of suicidal depression and PTSD as a national priority. For eligible drugs, the program… Read More NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to NRXP are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected] View the original release on
Associated Press
4 hours ago
- Associated Press
Iksuda Therapeutics Receives FDA IND Clearance for IKS014
NEWCASTLE, England--(BUSINESS WIRE)--Jun 30, 2025-- Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IKS014, a human epidermal growth factor receptor 2 (HER2) ADC targeting patients with advanced HER2+ solid tumours, enabling the expansion of ongoing clinical trials. IKS014 is currently being investigated in an open-label phase 1 dose-escalation study ( ) designed to evaluate the safety and tolerability of increasing dose levels of IKS014 and establish a recommended phase 2 dose. Preliminary data from this study has demonstrated promising clinical activity across multiple tumour types, including breast, ovarian, gallbladder, and oesophageal cancers, and including patients who have relapsed after prior treatment with Enhertu. Gaining access to U.S. centres for the dose expansion stage of this phase 1 trial will enable efficient confirmation of the role of IKS014 in this important patient sub-set. Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, said: 'The FDA clearance of our IND application for IKS014 represents a significant milestone in our mission to address the critical unmet needs of patients with HER2-positive cancers, particularly those who have exhausted current standard-of-care options. Early clinical data has been extremely encouraging, and we are excited to expand our program to reach more patients. 'The early efficacy signals that have been observed, particularly in patients that have relapsed after receiving prior treatments of Kadcyla and Enhertu, suggest IKS014 could potentially offer a new treatment option for patients who currently have limited alternatives. We look forward to working with our clinical partners to further evaluate the potential of IKS014.' The first stage of this phase 1 trial, to determine the recommended phase 2 dose for dose expansion, is nearing completion. The expansion phase will assess several patient cohorts including those with HER2-positive breast cancer who are refractory to or cannot tolerate Enhertu, patients with HER2-low breast cancer and patients with HER2-positive positive gastric cancer. The IND clearance will allow Iksuda to access patients across sites in the United States, alongside sites in Australia, New Zealand, and Singapore. The phase 1 trial is expected to complete in 2H 2026. About IKS014 IKS014 is a potential best-in-class antibody drug conjugate, benefiting from tumour selective activation and release of the cytotoxic agent monomethyl auristatin F (MMAF). In preclinical trials, it displayed impressive activity in high- and low-HER2 expressing tumours with a favourable Therapeutic Index vs other HER2-directed drugs. Iksuda gained exclusive world-wide rights (excluding Greater China and South Korea) to IKS014 from LigaChem Biosciences ( ). About Iksuda Therapeutics: Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda's pipeline of ADCs is centred on a portfolio of prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink ® platform. The Company's design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer. View source version on CONTACT: For further information please contact: Iksuda Therapeutics Dave Simpson, Chief Executive Officer Tel: +44 (0) 191 6031680 [email protected] Consulting (Financial Media and IR) Simon Conway / Rob Winder / Amy Byrne Tel: +44 (0) 020 3727 1000 [email protected] KEYWORD: NORTH AMERICA UNITED STATES IRELAND UNITED KINGDOM EUROPE MASSACHUSETTS INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH FDA CLINICAL TRIALS SOURCE: Iksuda Therapeutics Copyright Business Wire 2025. PUB: 06/30/2025 08:00 PM/DISC: 06/30/2025 08:00 PM
Health Line
5 hours ago
- Health Line
How to Dispose of Used Diabetes Supplies
To dispose of used diabetes supplies, use an FDA-cleared container for sharp medical supplies. This can help prevent injury from exposed needles when they're disposed of properly. Diabetes medical supplies play an important role in managing blood sugar and living a healthy life. But once you've used them up, figuring out how to dispose of the waste can be a chore. That can mean finding a place to discard used syringes and sharp needles, bloody test strips, old infusion sets, empty glass vials, or many other disposable parts that come with diabetes devices. Some of this may end up in the trash or recycle bin, heading to a disposal site along with Amazon boxes, empty water bottles, and trash going to a landfill. But for the rest, including sharp medical supplies, you may have to take more care in disposing of used diabetes items. Handling medical sharps The Food and Drug Administration (FDA) refers to these as 'sharps,' the medical term for supplies and devices with sharp points or edges that can puncture or cut your skin. For people with diabetes, this may include: lancets used to poke their fingers syringes or pen needle tips for injecting insulin insulin pump infusion sets and continuous glucose monitor (CGM) sensors that have tiny built-in needles to puncture the skin needles for certain forms of fast-acting glucagon used for severe hypoglycemia Generally, the public health risk tied to sharps disposal has been well-documented and monitored by the FDA along with healthcare professionals. This older study noted that people with diabetes are most likely to dispose of medical sharps in the 'most convenient manner,' which is often household trash. According to this 2023 research review, people who've lived with the condition longer are the least likely to dispose of medical sharps correctly. Those who have newly received the diagnosis tend to be more cautious when handling needles and medical sharps and disposing of used supplies. These findings echo an earlier 2018 study, in which researchers found those who'd lived with diabetes for 30 or more years were the least likely to dispose of medical sharps correctly. According to researchers, many people with diabetes didn't learn about proper disposal practices from healthcare professionals, but those who did had the highest rates of correctly disposing of diabetes supply waste. This Indonesia-based research, published in 2023, found that only healthcare professional training helped people improve their practices in disposing of diabetes supplies, particularly medical sharps like insulin syringes and pen needle caps. Yet, this 2024 research shows that people in Egypt with 'fair' knowledge of how to dispose of diabetes supplies may not always dispose of them correctly. How to dispose of used diabetes sharps You can dispose of and sometimes recycle sharps in special sharps containers, according to state and local rules. The FDA offers this website along with a Be Smart With Sharps campaign focused on safe sharps disposal. Some basics of that campaign are as follows: Used sharps should be immediately placed in a sharps disposal container. FDA-cleared sharps containers are generally available through pharmacies, medical supply companies, healthcare professionals, and online. These containers are made of puncture-resistant plastic with leak-resistant sides and bottoms. They also have a tight-fitting, puncture-resistant lid. Sharps containers come in many sizes, which can be important for certain supplies such as disposable insulin pens that are longer than some standard sharps containers can hold. If an FDA-cleared container is not available, a heavy-duty plastic household container, such as a laundry detergent container, can be used as an alternative. DO NOT USE milk jugs, soda cans, glass containers, or water bottles because they can break or puncture easily. Donation options A few national programs, such as the nonprofit Afya, accept donations of used medical supplies. Check with local used medical supply collection programs that may accept these types of used products. Each state and even local communities have different rules in place, so here's a guide to sharps disposal in each state. Insulin pump supplies and infusion sets The leftover parts from insulin pump use include the infusion sets (the piece inserted under your skin with a needle to enable insulin delivery) and the cartridges or reservoirs that hold the insulin inside the pump. You can include most of these pieces with sharps in those waste containers. Note that the 90-degree infusion sets (said to be more comfortable for people with smaller bodies) are compatible with all tubed pump brands. They come in plastic 'pods' with the infusion needle built in. While you can also dispose of those in sharps containers, they are a bit bulkier and take up more space. Some insulin pump brands create more waste than others. Medtronic and some other older, discontinued tubed pump brands have a cylinder reservoir that holds the insulin, with the infusion needle housed in a small part on top. You can dispose of both with other medical waste, but the needle part is sharp. Tandem's t:slim X2 is the only tubed pump that doesn't use a cylinder but a slim plastic cartridge with an insulin-containing bag inside. The t:slim supplies include a syringe and needle cap to fill the bag, the plastic cartridge, and a separate infusion set with tubing. None of the insulin pump companies in the United States have an official recycling program specific to their products. Insulet had a recycling program for Omnipod, but it was discontinued in 2018. Do-it-yourself diabetes supply disposal ideas Within the Diabetes Online Community, many people offer tips and tricks on what they do about recycling and disposing of old diabetes supplies. Do not put these directly into the trash or recycling bin as-is, because of the used needles inside. While some supplies are self-contained, they can still come apart. This can be dangerous for people picking up the recycling or coming into contact with it later on. Collect these supplies over time and then drop them off in bulk at a local sharps container facility that can process them accordingly. Disassemble the auto-inserters using a screwdriver and pliers to separate the parts and remove the sharp needle inside. Then, put the sharper metal items into a sharps container and recycle the rest of the plastic. Some people use thick containers, such as food containers or clear or colored jugs, once they're empty. This isn't recommended because some containers may be thinner than others — such as milk jugs or boxes — and sharps may poke through them and be dangerous. Those using glass or thicker plastic containers should label them to indicate 'hazardous medical sharps' inside. Try turning them into creative, crafty ideas. In #WeAreNotWaiting diabetes DIY groups online, you can regularly find instances where people have donated old transmitters and sensors to fellow experimenters to reuse for testing and building purposes. The takeaway You can dispose of used diabetes supplies in several ways, especially sharp medical supplies. These may include empty glass insulin vials or cartridges, insulin syringes, pen cap needles, glucose meter lancets, insulin pump infusion sets, or CGM supplies with built-in needles for inserting them into the skin. Medical sharps containers are the preferred disposal method. They can be found at certain doctors' offices, clinics, health facilities, or other locations. You can also buy them online or at medical supply stores. After filling those containers, check your local ordinances and state rules, which may provide more details on how and where you can properly dispose of these sharps containers.
